Clinical study on the efficacy and safety of eltrombopag olamine tablets in secondary prevention of chemotherapy-induced thrombocytopenia in rare tumors

Start Date10 Jul 2026

Sponsor / Collaborator-

NCT07788456

/ RecruitingPhase 4IIT

Efficacy and Safety of Multi-Target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia: A Prospective, Single-arm, Multicenter, Exploratory Trial

This prospective, single-arm, multicenter, exploratory study will enroll 38 adults patients with newly diagnosed primary immune thrombocytopenia (ITP). Patients will receive standard-dose corticosteroids plus a thrombopoietin receptor agonist (TPO-RA) as initial therapy During the core treatment phase (Weeks 1-12). Corticosteroids will be tapered and discontinued within 8 weeks, whereas TPO-RA treatment will continue for 12 weeks. For patients with treatment failure( defined as platelet count < 30 × 10^9/L or less than 2-fold increase of baseline platelet count or bleeding) ,a sequential multitarget combination strategy will be explored in subsequent treatment phases. Specifically, patients with treatment failure after 2 weeks of initial therapy (Weeks 3-12), will receive the ongoing TPO-RA in combination with either rituximab or an anti-CD38 monoclonal antibody（mAb） as sequential combination therapy.
During the core treatment follow-up phase (24 weeks), patients with treatment failure will enter the exploratory treatment phase (Weeks 13-36) .
Patients who received multi-target drug therapy during the core treatment period will switch to an alternative TPO-RA with cross-administered rituximab and anti-CD38 mAb, while those who did not will receive sequential rituximab or anti-CD38 mAb.
Finally, patients will enter the safety follow up period (4 weeks, weeks 37-40).

Start Date22 Jun 2026

Sponsor / Collaborator

Hematology Hospital of Chinese Academy of Medical Sciences

ChiCTR2600125575

/ Not yet recruitingNot ApplicableIIT

Hetrombopag combined with dexamethasone for the treatment of severe recurrent chemotherapy-induced thrombocytopenia (CTIT) in gastrointestinal tumors

Start Date01 Jun 2026

Sponsor / Collaborator-

100 Clinical Results associated with Herombopag Olamine

100 Translational Medicine associated with Herombopag Olamine

100 Patents (Medical) associated with Herombopag Olamine

Literatures (Medical) associated with Herombopag Olamine

31 Dec 2026·Hematology

Efficacy and safety of TPO-RA combined with sirolimus in the treatment of relapsed immune thrombocytopenia

Article

Author: Chen, Xiaoli ; Wang, Dan ; Feng, Yimei ; Zhang, Xi ; Liu, Jia ; Li, Jinqiong ; Tan, Aoxue

BACKGROUND:

Relapsed immune thrombocytopenia (ITP) poses challenges in treatment. Thrombopoietin receptor agonists (TPO-RAs) are recommended as second-line therapy, but the efficacy of monotherapy is limited to about 60%. Our preliminary studies suggest sirolimus is effective for relapsed ITP. This study aimed to evaluate the efficacy and safety of TPO-RA combined with sirolimus in treating relapsed ITP.

METHODS:

A retrospective analysis was conducted on 50 patients with relapsed ITP, all of whom received TPO-RAs (hetrombopag and eltrombopag) combined with sirolimus therapy. The primary endpoints were the overall response rate (ORR) at 4, 8, and 12 weeks of treatment. Secondary endpoints included safety of this regimen and subgroup analysis.

RESULTS:

ORR at 4, 8, and 12 weeks was 61%, 76%, and 82%, respectively, with a median time to response of 7 days. Mean platelet counts at 2-, 4-, 8-, and 12-weeks post-treatment were 71 ± 12.7 × 10⁹/L, 86 ± 10.9 × 10⁹/L, 128 ± 19.7 × 10⁹/L and 131 ± 17.2 × 10⁹/L, respectively. Whether it is hetrombopag or eltrombopag, when combined with sirolimus, there is no statistically significant difference in efficacy between the two subgroups. TPORAs combined with sirolimus as second-line treatment and as third-line or beyond treatment showed no difference in efficacy. Among ANA-positive patients, the ORR shows no significant difference compared to the ANA-negative group (p > 0.05). Patients with ITP for less than one year are more likely to benefit from this treatment regimen (p = 0.003).

CONCLUSIONS:

The combination of TPO-RAs and sirolimus significantly improved platelet counts and sustained response rates. The regimen demonstrated a manageable safety profile, offering a novel therapeutic option for relapsed ITP.

31 Dec 2026·PLATELETS

Single-cell transcriptome deciphers key targets of thrombopoietin receptor agonists and immune microenvironment characteristics of immune thrombocytopenia

Article

Author: Wan, Xiaohan ; Hou, Ming ; Wang, Haoxu ; Wang, Wanru ; Wang, Ruixue ; Cao, Junying

Thrombopoietin receptor agonists (TPO-RAs) represent a cornerstone in immune thrombocytopenia (ITP) management, yet their molecular mechanisms remain incompletely elucidated. This study systematically deciphered the key targets and signaling networks of four TPO-RAs (romiplostim, eltrombopag, avatrombopag, hetrombopag) in ITP pathogenesis. Network pharmacology was integrated with single-cell high-dimensional weighted gene co-expression network analysis (hdWGCNA) using bone marrow scRNA-seq data from ITP patients and healthy controls. Metacell-based co-expression modules to hematopoietic bone marrow cells were identified. Drug targets were curated from multiple databases, and candidate genes were screened by intersecting differentially expressed genes (DEGs), cell specific modules, and TPO-RA targets. Molecular docking, pseudotime trajectory analysis, and in silico gene knockdown were employed for functional validation. Intersection analysis revealed five key genes (CACNA1A, CSF1R, PKN1, CD9, DSTYK). Molecular docking demonstrated strong binding affinities between TPO-RAs and key targets. The ITP bone marrow niche exhibited rewired cell-cell communication, with enhanced T cell-initiated signaling and aberrant megakaryocyte-T cell interactions. Pseudotime analysis uncovered disrupted megakaryocyte maturation dynamics. In silico knockdown revealed CACNA1A, CSF1R, and PKN1 dysregulation exacerbated neutrophil hyperactivity, while CD9 and DSTYK knockdown impaired mitotic regulation. This study delineated mechanisms of TPO-RAs, highlighting five key genes that orchestrate dysregulated thrombopoiesis and immune dysfunction in ITP. The integration of in silico strategies identified novel targets for optimizing ITP therapy.

01 Jun 2026·Transplantation and Cellular Therapy

Evaluation of the Real-World Efficacy of Hetrombopag for the Treatment of Thrombocytopenia Postallogeneic Hematopoietic Stem Cell Transplantation

Article

Author: Huang, Xiao-Jun ; Luo, Xue-Yi ; Sun, Yu-Qian ; Ma, Rui ; Wei, Rong ; Sun, Jie ; Han, Wei

Persistent thrombocytopenia (PT), comprising delayed platelet engraftment (DPE) and secondary failure of platelet recovery (SFPR), is a severe complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT), occurring in up to 70% of recipients. PT is strongly associated with life-threatening hemorrhage, increased nonrelapse mortality, and reduced overall survival (OS). Current therapeutic options, including recombinant human thrombopoietin (rhTPO), CD34+ cell boosts, and mesenchymal stromal cell infusion, are limited by variable efficacy and procedural complexity. TPO receptor agonists (RAs) have shown promise in promoting megakaryopoiesis, yet their efficacy in the post-transplant setting remains heterogeneous. Hetrombopag, a novel oral TPO-RA with enhanced receptor affinity and a favorable safety profile, has demonstrated efficacy in immune thrombocytopenia and aplastic anemia, but its real-world utility in allo-HSCT-associated PT remains unexplored. This study aimed to evaluate the real-world efficacy and safety of hetrombopag in patients with PT following allo-HSCT, in order to improve outcomes for this high-risk population. This retrospective observational study enrolled 33 adult patients with PT (7 DPE, 26 SFPR) after allo-HSCT between June 2022 and April 2024. All patients received oral hetrombopag starting at 5 mg/d, with escalation to 7.5 mg/d if no response was observed within 1 wk. Treatment continued until platelet recovery, adverse events, or disease progression. The primary endpoint was the overall response rate (ORR), defined as sustained platelet recovery to ≥20 × 10⁹/L for ≥7 d without transfusion. Secondary endpoints included OS, relapse, graft-versus-host disease, and safety. Statistical analyses included Kaplan-Meier survival analysis, Cox regression, and nonparametric tests for variable comparisons. The median platelet count before treatment was 14 × 10⁹/L. Hetrombopag was initiated at a median of 56 d post-transplant, with a median treatment duration of 82 d. The ORR was 81.8% (27/33), with 100% response in DPE and 76.9% in SFPR subgroups. Among responders, median platelet counts increased from 14 to 80 × 10⁹/L, and megakaryocyte counts rose from 12 to 58 per smear. Notably, 6 of 7 patients with absent megakaryocytes at baseline responded to treatment. Of 11 patients previously unresponsive to rhTPO, 10 responded to hetrombopag. No significant predictors of complete response were identified in univariate analysis. Safety analysis revealed mild liver enzyme elevation in 4 patients (12.1%), with no grade 3 to 4 toxicities or treatment discontinuations. Hetrombopag demonstrates high efficacy and a favorable safety profile in the management of PT after allo-HSCT, including in patients with poor megakaryocyte reserves or prior rhTPO failure. These real-world findings support its use as a promising therapeutic option in this high-risk population. Further prospective, randomized studies are needed to validate these results and establish predictive biomarkers for optimal patient selection.

News (Medical) associated with Herombopag Olamine

20 Oct 2025

·www.prnewswire.com

Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power

BERLIN, Oct. 20, 2025 /PRNewswire/ -- From October 17 to 21, the European Society for Medical Oncology (ESMO) Annual Congress convened in Berlin, bringing together global leaders in oncology and pharmaceutical innovation. Representing China's advancing biopharmaceutical landscape, Hengrui Pharma not only returned with a comprehensive portfolio of oncology research but also debuted as an exhibitor, marking a new milestone in its global academic engagement. Since 2016, Hengrui has presented pioneering research at the ESMO Annual Congress for ten consecutive years. This year, the company unveiled 46 studies across 14 innovative therapeutic programs, including nine oral presentations, two mini oral sessions, and four late-breaking abstracts (LBAs), underscoring its global R&D strength. These data highlight the company's commitment to multi-cancer coverage and multi-mechanism innovation in oncology. In parallel, Hengrui scheduled a series of academic events, fostering in-depth dialogue with leading global experts and clinical researchers on cutting-edge topics in oncology. These initiatives established a dynamic platform for international academic exchange and infused Chinese innovation into the global landscape of cancer diagnosis and treatment – marking a new chapter in Hengrui's journey of international scientific engagement. As one of the world's premier oncology platforms, the ESMO Annual Congress attracts more than ten thousand experts and hundreds of leading international pharmaceutical companies each year. The meeting showcases the latest advances in cancer research and therapeutics, serving as a high-level hub for academic exchange and collaboration. It continues to catalyze innovation and clinical translation across the oncology community, aligning with the 2025 Congress vision: "Standing by those who care about cancer." Global Vision: China Innovation Going Global At the ESMO 2025 Annual Congress, Hengrui co-hosted the roundtable "China Innovation Going Global," bringing together leading Chinese and international experts to discuss strategic pathways and future prospects for the globalization of China-origin innovations. During the global launch of the CARES-009 study, featuring Hengrui's innovative therapeutic combination of camrelizumab and rivoceranib, Academician Jia Fan of the Chinese Academy of Sciences and Professor Jian Zhou of Zhongshan Hospital, Fudan University, jointly presented the latest global data from the study, garnering widespread attention from the international oncology community. Ms. Jo Feng, President and Chief Operating Officer of Hengrui Pharma, led the company's delegation at this year's Congress. She stated, "ESMO serves as a premier global platform for oncology exchange, and this year, Hengrui proudly presented 46 research achievements – highlighting our growing academic presence on the world stage. As an innovation-driven global pharmaceutical company, Hengrui places medical innovation at the heart of its strategic vision, with a steadfast commitment to addressing unmet clinical needs. Looking ahead, we remain firmly patient-centric, continuing to advance groundbreaking therapies to improve the lives of patients worldwide." Breakthroughs Across Multiple Cancer Types At this year's ESMO Annual Congress, Hengrui had 46 oncology research projects accepted, including four LBAs, spanning 14 innovative therapeutic programs. Among these, nine were selected for oral presentations, two for mini oral sessions, 32 as posters, and three as e-posters. Collectively, these studies encompass more than 10 cancer types, including esophagogastric cancer, gynecologic malignancies, liver cancer, breast cancer, pancreatic cancer, lung cancer, sarcoma, biliary tract cancer, head and neck squamous cell carcinoma, prostate cancer, and thyroid cancer. In breast cancer, Hengrui had 11 research studies accepted, comprising one oral presentation, one mini oral, eight posters, and one e-poster. Notably, an LBA featuring Hengrui's antibody-drug conjugate (ADC) trastuzumab rezetecan (SHR-A1811) compared with pyrotinib plus capecitabine for patients with HER2-positive advanced or metastatic breast cancer was selected for presentation. Multiple studies highlighting both established and emerging therapies, including pyrotinib, dalpiciclib, and adebrelimab, demonstrate Hengrui's deep and sustained commitment to advancing breast cancer research. In gastrointestinal cancers, 14 studies were accepted, including two oral presentations, 11 posters, and one e-poster. Alongside flagship therapies such as camrelizumab and rivoceranib, four studies on adebrelimab in the gastrointestinal field were featured. In addition, investigational agents including HRS-4642 (a KRAS G12D inhibitor) and SHR-1701 (a PD-L1/TGF-β bifunctional antibody) were also presented, reflecting the strong momentum of both Hengrui's established portfolio and emerging pipeline in advancing care for patients with gastrointestinal malignancies. In lung cancer, six poster presentations featuring camrelizumab and adebrelimab were accepted, underscoring Hengrui's expanding footprint in this therapeutic area. These studies covered both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), further validating the clinical potential and versatility of these regimens. Across additional disease areas, including gynecologic tumors, thymic epithelial tumors, head and neck squamous cell carcinoma, sarcoma, prostate cancer, and thyroid cancer, Hengrui had 13 studies accepted, featuring a diverse range of innovative therapies such as camrelizumab, fuzuloparib, rivoceranib, rezvilutamide, adebrelimab, famitinib, HRS-7058, and HRS-4642. These included six oral presentations, one mini oral, five posters, and one e-poster, highlighting Hengrui's robust and broad-based R&D capabilities. In addition, two posters were accepted on hetrombopag and ondansetron oral soluble films, focusing on the prevention and management of chemotherapy-induced thrombocytopenia, nausea, and vomiting. Dr. Frank Jiang, Executive Vice President and Chief Strategy Officer of Hengrui Pharma, stated: "At this year's ESMO Annual Congress, we unveiled a broader and more impactful portfolio of research findings. The concentrated release of these breakthrough data not only reflects Hengrui's robust R&D capabilities, but also highlights the results of our science-driven, globally oriented innovation R&D strategy. Our pipeline is both deep and forward-looking – while reinforcing our existing product portfolio, we are also actively expanding into cutting-edge therapeutic areas. We firmly believe that through this in-depth engagement with the global oncology community, we can better enable our breakthroughs to benefit more patients worldwide." A Decade of ESMO Participation: China Innovation Going Global Since 2016, Hengrui Oncology has participated in the ESMO Annual Congress for 10 consecutive years, consistently setting new benchmarks for Chinese pharmaceutical companies. Between 2023 and 2025, Hengrui presented a total of 119 research achievements: 2023: 36 studies accepted, including two preferred oral presentations, six mini oral presentations, and 28 posters, covering multiple therapeutic areas such as gastrointestinal cancers, breast cancer, cervical cancer, pancreatic cancer, and melanoma. 2024: 37 studies accepted, spanning 13 innovative therapies and more than 10 cancer types, including esophagogastric cancer, gynecologic malignancies, liver cancer, breast cancer, and lung cancer. 2025: Marking its first-ever exhibition booth at ESMO, Hengrui presented 46 studies across 14 innovative medicines. This milestone represents a significant step forward in Hengrui's internationalization strategy and its commitment to advancing global cancer care. Commitment to Global Impact with the Promise of Patient Focus Hengrui remains steadfast in its commitment to science and innovation driven by the goal of addressing unmet patient needs. Leveraging a global R&D network, the company is advancing innovative medicines onto the international stage. Through a strategically structured pipeline, continuous breakthroughs across multiple cancer types, and active participation in global academic exchange, Hengrui Oncology is accelerating the internationalization and bringing new hope and broader treatment options to patients worldwide. About Hengrui Pharma Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Founded in 1970 with the core principle of putting patients first, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. About Hengrui Oncology Hengrui Oncology specializes in the development, production, and global commercialization of innovative cancer therapies. It is the first business unit within Hengrui to achieve technological breakthroughs and successfully enter international markets. Hengrui Oncology has established a robust and diversified oncology pipeline encompassing multiple tumor types, with a comprehensive portfolio that includes immunotherapies, targeted therapies, and ADCs. In key areas such as breast cancer, Hengrui Oncology provides full-course treatment solutions that span multiple lines of therapy. To date, 14 novel oncology agents developed by Hengrui have been approved for marketing in China. SOURCE Hengrui Pharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ASCOImmunotherapyDrug Approval

08 Jan 2024

·synapse.patsnap.com

TPO receptor agonists: What They Are and How to Stay Updated on the Latest Research

The TPO receptor, also known as the thrombopoietin receptor, plays a crucial role in the human body's production of platelets. Thrombopoietin, a hormone produced in the liver and kidneys, binds to the TPO receptor, stimulating the production and maturation of megakaryocytes, which are the precursor cells of platelets. This interaction is essential for maintaining adequate platelet levels in the blood, which are vital for normal blood clotting and preventing excessive bleeding. Understanding the TPO receptor's function has led to the development of drugs that target this receptor, offering potential therapeutic options for conditions associated with low platelet counts, such as immune thrombocytopenia and chemotherapy-induced thrombocytopenia. The analysis of the target TPO receptor reveals a competitive landscape with multiple companies actively involved in research and development. The highest stage of development is the "Approved" phase, with several companies having drugs in this phase. Thrombocytopenia and Purpura, Thrombocytopenic, Idiopathic are the most common indications for drugs under this target. Small molecule drugs, Fusion proteins, and Biosimilars are progressing most rapidly, indicating intense competition. China, the United States, the European Union, and Japan are the leading countries in terms of development under this target. Further analysis is required to understand the specific R&D progress of each company, the research institutions involved in biosimilar development, and the factors contributing to the progress in China. How do they work?TPO receptor agonists are a type of medication that act on the thrombopoietin (TPO) receptor in the body. Thrombopoietin is a hormone that regulates the production of platelets, which are essential for blood clotting. TPO receptor agonists mimic the action of thrombopoietin and stimulate the production of platelets in the bone marrow. From a biomedical perspective, TPO receptor agonists are used in the treatment of certain medical conditions that result in low platelet counts, such as immune thrombocytopenia (ITP) and chemotherapy-induced thrombocytopenia. By increasing platelet production, these medications help prevent bleeding episodes and improve overall blood clotting function. TPO receptor agonists can be administered orally or through injection, depending on the specific drug. They work by binding to the TPO receptor on the surface of bone marrow cells, which triggers a signaling cascade leading to increased platelet production. These medications are typically used when other treatments, such as corticosteroids, have been ineffective or are not suitable for the patient. It is important to note that TPO receptor agonists may have potential side effects, such as headache, nausea, fatigue, and muscle pain. Close monitoring of platelet counts and regular follow-up with a healthcare professional are necessary during treatment with these medications to ensure optimal effectiveness and safety. List of TPO receptor AgonistsThe currently marketed TPO receptor agonists include: Herombopag OlamineLusutrombopagAvatrombopag MaleateEltrombopag DiolamineRomiplostimRecombinant human thrombopoietin(Shenyang Sunshine Pharmaceutical)Eltrombopag cholineNIP-022NIP-022SCB-219MFor more information, please click on the image below. What are TPO receptor agonists used for?TPO receptor agonists are used in the treatment of certain medical conditions that result in low platelet counts, such as immune thrombocytopenia (ITP) and chemotherapy-induced thrombocytopenia. For more information, please click on the image below to log in and search. How to obtain the latest development progress of TPO receptor agonists?In the Synapse database, you can keep abreast of the latest research and development advances of TPO receptor agonists anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

100 Deals associated with Herombopag Olamine

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	B02BX	DB16184

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Thrombocytopenia	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	08 Sep 2026
Anemia, Aplastic	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	16 Jun 2021
Chronic thrombocytopenia	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	16 Jun 2021
Purpura, Thrombocytopenic, Idiopathic	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	16 Jun 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic liver disease	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	31 Jul 2024
Bladder Cancer	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Nov 2019
Breast Cancer	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Nov 2019
Lymphoma	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Nov 2019
Non-Small Cell Lung Cancer	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Nov 2019
Pancreatic Cancer	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Nov 2019
Solid tumor	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Nov 2019
Refractory Severe Aplastic Anemia	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	05 Mar 2019
Lung Cancer	Phase 2	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	01 Aug 2025
Metastatic Lung Cancer	Phase 2	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	01 Aug 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ChiCTR2400086043 (ASCO2026)	Phase 2	Solid tumor	65	Hetrombopag 5 mg QD plus Caffeic Acid Tablets 0.3 g TID	efoesyolay(afwneajrud) = izgyvqqabu boywpackqf (tncyelncrz ) View more	Positive	29 May 2026
NCT06099925 (ASCO2026)	Phase 2	Female Genital Neoplasms	43	Hetrombopag 5 mg	wswdumhlrj(dkwnrpcnhh) = Hetrombopag was well tolerated, with no treatment-related adverse events clkmyzjpip (htuzkxwpnb )	Positive	29 May 2026
EHA2026	Not Applicable	Multiple Myeloma \| Hematologic Neoplasms \| Lymphoma	55	Hetrombopag	njtzfudygc(foivwcquwm) = All adverse events were grade 1-2 and resolved with symptomatic management. Common events included fever, headache, dizziness, diarrhea, fatigue, rash, elevated transaminases, and renal dysfunction. No grade ≥3 adverse events were observed. lnwkjjrsex (gpunseuukp ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Multiple Myeloma \| Hematologic Neoplasms \| Lymphoma	55	Eltrombopag		Positive	12 May 2026
NCT05442632 (EHA2026)	Phase 4	Hepatocellular Carcinoma	69	Hetrombopag 5 mg	icunrubgnu(dgpcagmbjz) = bjzycgxdty rjjttfbozl (qpgwkkmttr ) View more	Positive	12 May 2026
NCT05442632 (EHA2026)	Phase 4	Hepatocellular Carcinoma	69	Placebo	icunrubgnu(dgpcagmbjz) = dhqaketipq rjjttfbozl (qpgwkkmttr ) View more	Positive	12 May 2026
ChiCTR2500106644 (EHA2026)	Phase 4	Thrombocytopenia	25	Hetrombopag 7.5 mg	uhiscorxmh(yflafgekew) = lxmzcvoybp uzzbdnzlrk (yuoguwfmuo ) View more	Positive	12 May 2026
ChiCTR2400094077 (EHA2026)	Phase 4	Thrombocytopenia	20	Hetrombopag 7.5mg	wcjrvmsklq(etjnlmiqxm) = one patient experienced grade 3 anemia, one had a grade 3 febrile neutropenia, one had a grade 4 pulmonary infection, all of which were deemed unrelated to hetrombopag treatment. yglrwxbygx (lfyutcvwep ) View more	Positive	12 May 2026
EHA2026	Phase 2	Purpura, Thrombocytopenic, Idiopathic First line	49	Hetrombopag combined with prednisone	wpgrbqobpu(rmwzeulcxt) = No related thrombotic events or hepatotoxicity were observed. byeitfxnne (ipzwqhbnav )	Positive	12 May 2026
EHA2026	Phase 4	Refractory Severe Aplastic Anemia First line	54	Hetrombopag + ImmunSuppressive Therapy	plyjvtqbzv(akbvvpqttk) = jcuztafxal cgzzbkjaqi (mhewpgyncz ) View more	Negative	12 May 2026
EHA2026	Phase 4	Refractory Severe Aplastic Anemia First line	54	Immunosuppressive Therapy	plyjvtqbzv(akbvvpqttk) = kiijwtkbyh cgzzbkjaqi (mhewpgyncz ) View more	Negative	12 May 2026
EHA2026	Not Applicable	Thrombocytopenia \| Myelodysplastic Syndromes	56	Hetrombopag	mimhbosmur(pbciapnlmj) = evqciesxob dicktjdqrl (qqgftfuhtu ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Thrombocytopenia	75	Hetrombopag (Chemotherapy-induced thrombocytopenia)	uyyfysdbdf(porquiggww) = vrlasezwqw ubzvapbdus (dsklkjlupk, 35.2 - 58.5) View more	Positive	12 May 2026
EHA2026	Not Applicable	Thrombocytopenia	75	Hetrombopag (gastric cancer)	uyyfysdbdf(dubqmwdiiq) = htsqpudewh nwqhzjevhe (pswarbijwo )	Positive	12 May 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis